Immunological Variables Associated With Clinical and Endoscopic Response to Vedolizumab in Patients With Inflammatory Bowel Diseases.,Journal of Crohn's and Colitis

当前位置： X-MOL 学术 › J. Crohns Colitis › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Immunological Variables Associated With Clinical and Endoscopic Response to Vedolizumab in Patients With Inflammatory Bowel Diseases.
Journal of Crohn's and Colitis ( IF 8.3 ) Pub Date : 2020-02-26 , DOI: 10.1093/ecco-jcc/jjaa035
Marina Coletta ₁ , Moira Paroni _{2,

3} , Maria Francesca Alvisi ₄ , Matilde De Luca ₄ , Eliana Rulli ₄ , Stefano Mazza ₁ , Federica Facciotti ₅ , Georgia Lattanzi ₅ , Francesco Strati ₅ , Sergio Abrignani _{2,

6} , Massimo Claudio Fantini ₇ , Maurizio Vecchi _{1,

8} , Jens Geginat ₂ , Flavio Caprioli _{1,

8}

Affiliation

Vedolizumab [VDZ] is a monoclonal antibody directed against the α4β7 integrin heterodimer, approved for patients with inflammatory bowel diseases [IBD]. This study aimed at identifying immunological variables associated with response to vedolizumab in patients with ulcerative colitis [UC] and Crohn’s disease [CD].

中文翻译：